Levodopa/Carbidopa Fairmed

Levodopa, the active ingredient in Levodopa/Carbidopa Fairmed, is an Antiparkinson agent presented as an oral tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in adult patients by restoring dopamine levels in the brain.

GNH USA supplies Levodopa/Carbidopa Fairmed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Clients receive reliable delivery timelines and comprehensive documentation for import compliance.

Levodopa/Carbidopa is indicated for disorders involving dopamine deficiency within the Parkinsonian disease spectrum. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor deficits in secondary parkinsonism. - Motor fluctuations in Parkinson's disease: reduces “off” periods and enhances overall functional mobility.

Levodopa/Carbidopa may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension or syncope - Cardiac arrhythmias

When prescribing Levodopa/Carbidopa, clinicians should observe several safety considerations. - Monitor blood pressure: watch for orthostatic drops especially after dose initiation. - Assess psychiatric status: observe for hallucinations, confusion or mood changes. - Adjust dose in renal impairment: reduce dosage in patients with severe renal dysfunction. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal or neuroleptic malignant‑like syndrome. - Use with caution in the elderly: increased susceptibility to dizziness and falls. - Store at below 25°C: keep in the original container, protect from moisture and light.

Levodopa/Carbidopa interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Selective MAO‑B inhibitors combined with non‑selective MAO inhibitors: can cause severe hypertension. - Antipsychotics that block dopamine receptors (e.g., haloperidol): may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Iron or calcium supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - Vitamin B6 (pyridoxine) at high doses: enhances peripheral levodopa metabolism. - High‑protein meals: compete for transport across the blood‑brain barrier, potentially lowering efficacy. - Antihypertensive agents: additive blood‑pressure‑lowering effect may require monitoring.